🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Challenge

Cases of gonorrhoea are on the rise around the world, with data suggesting over 82 million new cases each year. Particularly high rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs currently available.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Receive Approval

Zoliflodacin, marketed under the name a brand name, was authorized by the US FDA in recent days for treating gonorrhoea. This STI can lead to major issues, including infertility. Experts anticipate that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a innovative non-profit model for medication research. The charitable organization GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Outcomes and Global Access

Based on findings released by a prominent scientific publication, the new drug cured more than 90% of genital gonorrhoea infections. This puts it on an comparable level with the existing first-line therapy, which involves a dual-drug approach. The trial enrolled hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the ability to register and commercialise the drug in many regions with limited resources.

Clinicians treating patients have expressed hope. Access to a single-dose, oral treatment of this kind is described as a "critical tool" for managing the epidemic. This is viewed as vital to alleviate the strain of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.